Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/a622687e-ec18-4cc0-88dd-9821b08b2e8d/

RDY

Dr. Reddy’s Laboratories Ltd ADR
Chart
$13.24
Latest Week 2026-06-05
Snapshot 2026-06-07 · 0.0w · Fresh
0.85
OS Score
99.0%
Value
63.0%
Quality
16.0%
Momentum
#64.00000000
TV Rank
4/9
F-Score
0.790
QV
Strategy Eligibility
8 of 23 passing
OS Composite
OS 0.850
Trending Value
Quality × Value
QV 0.790
🏛
Cornerstone Value
🌿
Cornerstone Growth
P/S 0.0
💎
Deep Value
VC2 Cheapest
VC2 1.00000000
📐
EBITDA/EV
103.6%
Veiled Value
Piotroski Bargains
🔬
Quality Compounders
📈
Consistent Earners
Noneyr
🌱
GARP
🔄
Shareholder Yield
61.6%
💰
High Yield
Div 61.6%
🚀
Momentum Leaders
Market Leaders
Tiny Titans
🔍
Small Cap Value
🛡
Low Volatility
🏷
Sector Cheapest
🧠
Capital Allocators
Risk-Adj Momentum
V
Value Analysis
Cheapness relative to fundamentals
99.0%ile
P/E
0.3×
P/S
0.0×
P/B
0.0×
E/P
3.8798
FCF Yield
1.233
EBITDA/EV
1.036
SH Yield
0.616
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
1.00000000
/100 — 1=cheapest
VC2 (Trending Value)
1.00000000
/100
VC3 (Buyback)
1.00000000
/100
P/E of 0.3x places this firmly in deep value territory. FCF yield of 123.3% is strong — the business generates significant free cash relative to price. VC2 score of 1.00000000/100 puts this in the cheapest decile of the universe — prime Trending Value territory.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
63.0%ile
ROE
0.116
ROA
0.076
Net Margin
0.127
Op Margin
0.161
GPA
0.313
D/E
0.53
Current
1.80
F-Score
4/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.036
Earn Growth
-0.242
Stability
0.344
lower=better
Accruals
-0.024
lower=better
5yr Consist
Yes
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
16.0%ile
6M Return
-6.7%
12M Return
-14.3%
12-1 Mom
-14.4%
Risk-Adj
-0.75
Vol 252d
19.1%
Vol 60d
42.9%
↑ Expanding
Max DD 12M
-17.7%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of -14% signals a downtrend — price is moving against you. Near-term vol (43%) is expanding vs long-term (19%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.85
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
Sector Context
Healthcare · 500 peers
Sector Value %ile
100.0%
Sector Quality %ile
76.6%
P/E z-score
-0.45
P/B z-score
-0.41
Sector Avg OS
63.2%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
IRWD Ironwood Pharmaceuticals Inc 99.0% 93.0% 86.0% 98.0%
RIGL Rigel Pharmaceuticals Inc 98.0% 94.0% 92.0% 76.0%
FBIO Fortress Biotech Inc 98.0% 97.0% 93.0% 74.0%
WW WW International, Inc. Common Stock 97.0% 88.0% 80.0% 99.0%
PBYI Puma Biotechnology Inc 97.0% 80.0% 97.0% 92.0%
CGEN Compugen 97.0% 90.0% 95.0% 76.0%
FBIOP Fortress Biotech Inc Pref Series A 97.0% 81.0% 95.0% 90.0%
MD Mednax Inc 96.0% 87.0% 80.0% 87.0%
Factor Interactions
Falling Knife
Weak momentum (16th) despite looking cheap (99th value). Wait for momentum to stabilise.
Strong Capital Return
Shareholder yield 61.6% backed by 123.3% FCF yield. Returns are well-funded.
Volatility Expanding
60-day vol (43%) significantly exceeds 252-day (19%). Near-term risk is elevated.
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
A
100.0% avg (7 factors)
Quality
C
57.7% avg (8 factors)
Momentum
F
16.7% avg (4 factors)
Risk
A
84.9% avg (1 factors)
Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.850—1
Value %ile0.990—1
Quality %ile0.630—0
Momentum %ile0.160—1
F-Score4.000—1
Confidence1.000—1
Volatility0.191—1
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
0.26
Earnings Yield (E/P)
3.8798
Price / Sales
0.03
Price / Book
0.03
Price / Cash Flow
0.20
FCF Yield
123.3%
EBITDA / EV
103.6%
Sales Yield (1/P·S)
4.6793
Shareholder Yield
Div + net buyback / mktcap
61.6%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
11.6%
Return on Assets
7.6%
Net Margin
12.7%
Operating Margin
16.1%
Gross Profit / Assets
Novy-Marx GPA
31.3%
Debt / Equity
0.53
Current Ratio
1.80
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.024
MomentumPrice trend strength over different horizons
6M Return
-6.7%
12M Return
-14.3%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
-14.4%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
-0.75
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
3.6%
Earnings Growth (YoY)
-24.2%
Earnings Stability (CV)
Lower = more stable
0.344
5yr Consistent
EPS up every year for 5 years
Yes
Piotroski F-Score
4
Dividend Yield
61.6%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
1
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
1
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
1
Trending Value Rank
1=best. Top VC2 decile by 6M momentum
64
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity